Phil Mason, a CT and Transplant ICU Medical Director and ECMO expert, teams up with Brandon Parker, an Assistant Professor of Surgery and Medical Director of the Trauma ECMO Program, to dive deep into the world of ECMO for trauma patients. They discuss the nuances between VV and VA ECMO, highlighting key clinical trials like CESAR and EOLIA. The conversation explores patient selection, the importance of timely intervention, and the challenges of managing complex cases. They also speculate on future innovations in ECMO technology that could enhance patient outcomes.
ECMO, particularly VV and VA types, plays a critical role in managing severe respiratory and cardiac failure in trauma patients.
Significant trials like CESAR and EOLIA underscore the importance of specialized ECMO centers for optimal patient outcomes despite inconclusive survival benefits.
The future of ECMO in trauma care is promising with ongoing research into innovative strategies and advancements that aim to improve safety and effectiveness.
Deep dives
Introduction to ECMO in Trauma Surgery
Extracorporeal Membrane Oxygenation (ECMO) is increasingly recognized as a vital tool in trauma surgery, specifically for managing severe respiratory and cardiac failure. Veno-venous (VV) ECMO is primarily indicated for patients with respiratory failure, allowing for lung support through a bypass system that oxygenates blood outside the body. Conversely, veno-arterial (VA) ECMO provides both respiratory and cardiac support, making it a suitable choice in cases where cardiac output is critically low. Real-life examples illustrate ECMO's effectiveness as a bridge to recovery, particularly in cases of severe blunt thoracic trauma where traditional treatments fail.
Key Differences Between VV and VA ECMO
VV ECMO functions primarily to support patients with severe respiratory issues, utilizing large drainage and return cannulas typically placed in the femoral vein and right internal jugular vein. It operates by draining venous blood, oxygenating it, and then returning it to circulation while stabilizing the patient's respiratory status. VA ECMO, on the other hand, adds cardiac output management by reintroducing blood into the aorta from which it can be redistributed throughout the body. While VA ECMO is less commonly used in trauma due to frequent hypovolemic conditions, it is essential in scenarios where patients require simultaneous support for both respiratory and cardiovascular systems.
Controversial Evidence and Trials
Significant trials, such as CESAR and EOLIA, have shaped the understanding of ECMO's effectiveness, primarily focusing on ARDS populations rather than trauma patients. The CESAR trial indicated potential benefits in transferring patients to specialized ECMO centers, emphasizing the value of experienced care over therapy alone. EOLIA, while proving inconclusive in survival benefits, highlighted the complexity of managing severe ARDS when some patients crossed over to ECMO from the control group. These findings point to the necessity for further research into ECMO's role in trauma and the impact of early interventions by specialized centers.
ECMO Utilization and Challenges in Trauma Care
In trauma care, ECMO presents challenges, especially regarding indications, potential complications, and ethical considerations, including anticoagulation use. Popular indications for ECMO in trauma consist of severe blunt thoracic injuries causing respiratory failure and extended damage control strategies in critical situations. Despite its benefits, complications such as hemorrhage, limb ischemia, and coagulopathy remain considerations that clinicians must navigate carefully. Moreover, outcomes demonstrate that while the survival rate for trauma patients undergoing ECMO is promising, individualized patient assessment remains crucial to maximize benefits.
Future Directions in Trauma ECMO
The future of ECMO in trauma care looks promising with ongoing technological advancements and research into its utilization. Innovative approaches, including incorporating metabolic resuscitation strategies and potential non-anticoagulant therapies, are being explored to enhance efficacy while minimizing risks. Additionally, expanding the role of ECMO transport teams, ensuring that expertise and equipment reach trauma patients swiftly, is seen as vital. Furthermore, advancements in ECMO systems could reduce complications, and facilitate broader applications in diverse trauma scenarios across various healthcare settings.
Moderators Dr. Lauren Craugh and Dr. Zaf Qasim join guests Dr. Phil Mason and Dr. Brandon Parker as they discuss the use of ECMO in trauma patients. They cover the details of both VV and VA ECMO, patient selection, the latest literature and more!!
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode